Media.Player

New Treatment for Sepsis

詳細技術說明

Nitric oxide (NO) is produced in high quantities during sepsis and plays a major role in the development of hypotension. Cobalamin is known from previous studies in animal models to scavenge NO and to reduce mortality from septic shock. Researchers at UCSD have recently discovered that the cobalamin precursor cobinamide binds NO with 100 times greater affinity than cobalamin (Reactions of Nitric Oxide with Vitimin B12 and its Precursor, Cobinamide). They have developed a rapid and inexpensive method to produce cobinamide and have found that cobinamide, like cobalamin, shows no evidence of toxicity in rodent and human cells. Cobinamide has the potential to be extremely valuable in the treatment of septic shock.

*Abstract

Septic shock occurs from an overwhelming bacterial infection and is characterized by severe hypotension with low blood flow. It is the 13th leading cause of death in the United States with a mortality rate of 30%-50% due to the lack of effective treatments. In addition to the devastating effects of this syndrome on individuals, it incurs billions of dollars annually in healthcare costs.

*IP Issue Date

Apr 30, 2013

*Principal Investigation

Name: Gerry Boss

Department:

Name: Kate Broderick

Department:

Name: Vijay Sharma

Department:

Name: Matthew Brenner

Department:

Name: Antoni Chan

Department:

Name: Adriano Chan

Department:

Name: Sari Brenner Mahon

Department:

Name: Vikhyat Bebarta

Department:

Name: Karen Christman

Department:

Name: Jingjing Jiang

Department:

Name: Jean Wang

Department:

附加資料

Patent Number: US8431561B2
Application Number: US2006630049A
Inventor: Boss, Gerry | Sharma, Vijay | Broderick, Kate E.
Priority Date: 18 Jun 2004
Priority Number: US8431561B2
Application Date: 2 May 2008
Publication Date: 30 Apr 2013
IPC Current: A61K0031555 | A61K003170
US Class: 514186 | 514052
Assignee Applicant: The Regents of the University of California
Title: Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
Usefulness: Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
Summary: Used for the treatment of disease states caused or exacerbated by the presence of excess nitric oxide (NO), particularly sepsis, chronic liver failure, cirrhosis, hepatic cardiomyopathy, hemodialysis-related hypotension, cardiogenic shock, ischemia-reperfusion injury, hypoxia and trauma, for alleviating the symptoms of a disease state in a subject (e.g. cigarette smoker or hemodialysis patient) diagnosed as suffering from or at risk of developing a disease state caused or exacerbated by the presence of excess NO or cyanide caused by weapons of mass destruction e.g. cystic fibrosis, for the treatment of disease state in a subject (e.g. cigarette smoker or hemodialysis patient) caused or exacerbated by the presence of excess cyanide caused by weapons of mass destruction e.g. cystic fibrosis, for treating cyanide toxicity and smoke inhalation and for treating side effects associated with administration of nitroprusside (all claimed).
Novelty: Composition used for treatment of disease state caused or exacerbated by presence of excess nitric oxide e.g. sepsis comprises cobinamide and carrier

主要類別

診斷/治療

細分類別

其他疾病

申請號碼

8431561

其他

Additional Technologies by these Inventors

• Treatment for Smoke Inhalation and Cyanide Poisoning
• A Novel Nitric-Oxide Releasing Drug

Tech ID/UC Case

19491/2003-034-0

Related Cases

2003-034-0

國家/地區

美國